Kimberly Moran

TL;DR: The results from this post hoc analysis of the RECOVER study suggest that pain was improved in patients with PD treated with rotigotine; this may be partly attributable to benefits in motor function and sleep disturbances.

TL;DR: This study provides Class I evidence that for patients with moderate to severe RLS, rotigotine at optimal dose (1–3 mg/24 h) reduced PLM-associated nocturnal systolic blood pressure (SBP) elevations.

TL;DR: Non-compliance is prevalent within the general USA PD population and is associated with a recent PD diagnosis, certain comorbidities, and multiple daily treatment dosing, which may contribute to sub-optimal compliance.

TL;DR: Correlations between theIRLS and comparator scales were substantial and indicate that the IRLS is clinically meaningful, as there was a trend towards increasing IRLS severity category with increasing CGI-1, RLS-6, and R LS-QoL score.

TL;DR: There was only a small correlation between severity of early-morning motor Symptoms and overall burden of NMS and nocturnal sleep disturbances in RECOVER, suggesting that motor symptoms and NMS originate, at least partly, from distinct pathophysiological pathways.